华法林联合低分子肝素治疗颅内静脉窦血栓的临床研究

Clinical Study on Warfarin Combined with Low Molecular Weight Heparin in the Treatment of Cerebral Venous Sinus Thrombosis

目的探讨华法林联合低分子肝素治疗颅内静脉窦血栓的临床疗效。方法将我院收治的66例颅内静脉窦血栓患者随机分为对照组和研究组,各33例。对照组采用低分子量肝素注射液治疗,研究组采用低分子量肝素注射液联合华法林治疗。比较两组患者的临床疗效、 mRS评分、治疗前后的颅内压及PT。结果研究组的总有效率为87.88%,高于对照组的63.64%(P<0.05)。治疗后,研究组的颅内压和mRS评分均低于对照组(P <0.05), PT长于对照组(P <0.05)。结论华法林联合低分子肝素治疗颅内静脉窦血栓患者的临床疗效显著,可降低患者的颅内压,显著改善其血液凝集状况,预后良好。

Objective To explore the clinical efficacy of warfarin combined with low molecular weight heparin in the treatment of cerebral venous sinus thrombosis. Methods 66 cases of patients with cerebral venous sinus thrombosis admitted to our hospital were randomly divided into control group and study group, with 33 cases in each group. The control group was treated with low molecular weight heparin injection, while the study group was treated low molecular weight heparin injection combined with warfarin. The clinical efficacy,m RS score, and intracranial pressure and PT before and after treatment were compared between the two groups. Results The total effective rate of the study group was 87.88%, higher than 63.64% of the control group(P<0.05). After treatment, the intracranial pressure and m RS score of the study group were lower than those of the control group, and the PT was longer than that of the control group(all P<0.05).Conclusions Warfarin combined with low molecular weight heparin in the treatment of cerebral venous sinus thrombosis has significant clinical efficacy, which can reduce patients’ intracranial pressure and significantly improve the blood coagulation, with good prognosis.